Literature DB >> 6170921

Inhibitory effects of human leukocyte and fibroblast interferons on normal and chronic myelogenous leukemic granulocytic progenitor cells.

C K Williams, I Svet-Moldavskaya, J Vilcek, T Ohnuma, J F Holland.   

Abstract

Inhibitory effects of two human interferon preparations, leukocyte interferon (Le-IF) and fibroblast interferon (F-IF), on granulocytic progenitor cells (CFU-C) from hematologically normal cancer patients and from patients with chronic myelogenous leukemia were evaluated. There was a wide variation in sensitivity of CFU-C to both Le-IF and F-IF. F-IF was mor inhibitory against CFU-C than le-If. Normal CFU-C and chronic myelogenous leukemia CFU-C were equally inhibited by both interferons. Effects of both interferons were neutralized by corresponding specific antisera but not by the other antisera. These observations confirmed that differences in immunogenicity of the interferons may attend their different origins.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6170921     DOI: 10.1159/000225587

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  7 in total

1.  Response to the combined administration of interferons alpha and gamma after failure of single interferon therapy in chronic myelogenous leukaemia.

Authors:  O Kloke; R Becher; N Niederle
Journal:  Blut       Date:  1987-11

2.  Interferon alfa-2b in the treatment of chronic granulocytic leukemia.

Authors:  D E Bergsagel; R H Haas; H A Messner
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

3.  Treatment with natural human interferon alpha of a CML-patient with antibodies to recombinant interferon alpha-2b.

Authors:  M Freund; P von Wussow; J Knüver-Hopf; H Mohr; U Pohl; G Exeriede; H Link; H J Wilke; H Poliwoda
Journal:  Blut       Date:  1988-11

4.  Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM.

Authors:  M Y Gordon; S B Marley; J L Lewis; R J Davidson; D X Nguyen; F H Grand; T A Amos; J M Goldman
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

5.  Experience with human lymphoblastoid interferon in acute myelogenous leukaemia (AML).

Authors:  A Z Rohatiner; F R Balkwill; J S Malpas; T A Lister
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

6.  Treatment of chronic myelogenous leukemia with recombinant interferon alfa-2b.

Authors:  N Niederle; O Kloke; D May; R Becher; R Osieka; C G Schmidt
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

Review 7.  The role of interferons in the treatment of malignant neoplasms.

Authors:  J R Murren; A C Buzaid
Journal:  Yale J Biol Med       Date:  1989 May-Jun
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.